AC Immune SA

AC Immune SA's next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, AC Immune SA has 99.43M shares outstanding.

As of June 30, 2026, AC Immune SA maintains a current ratio of 0.93, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.66, indicating elevated leverage, while an interest coverage ratio of -200.41 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, AC Immune SA posted a negative return on equity (ROE) of -78.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -25.34, reflecting losses generated across the asset base. The company generates approximately 141,050.95 in revenue per employee across its workforce of 134.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, AC Immune SA generated 18.97M in revenue and converted that into -46.76M in net income, yielding earnings per share of -0.48. EBITDA reached -46.47M, while operating income came in at -47.35M.

As of June 30, 2026, AC Immune SA holds 81.65M in cash and equivalents against 4.44M in total debt, resulting in a net debt position of -30.08M. Total book value stands at 38.11M, with working capital of -7.41M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -249.59 and net profit margin of -246.49 provide insight into operational efficiency.